Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
- PMID: 34971806
- DOI: 10.1016/j.cgh.2021.12.034
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
Abstract
Background & aims: Fibrosis-4 (FIB-4) and the nonalcoholic fatty liver disease fibrosis score (NFS) are the 2 most popular noninvasive blood-based serum tests proposed for widespread fibrosis screening. We therefore aimed to describe the accuracy of FIB-4 and NFS to detect elevated liver stiffness as an indicator of hepatic fibrosis in low-prevalence populations.
Methods: This study included a total of 5129 patients with concomitant measurement of FIB-4, NFS, and liver stiffness measurement (LSM) by Fibroscan (Echosens, France) from 5 independent population-based cohorts from Spain, Hong Kong, Denmark, England, and France; 3979 participants from the general population and 1150 from at-risk cohorts due to alcohol, diabetes, or obesity. We correlated LSM with FIB-4 and NFS, and calculated pre- and post-test predictive values of FIB-4 and NFS to detect elevated LSM at 8 kPa and 12 kPa cutoffs. The mean age was 53 ± 12 years, the mean body mass index was 27 ± 5 kg/m2, and 2439 (57%) were women. One in 10 patients (552; 11%) had liver stiffness ≥8 kPa, but 239 of those (43%) had a normal FIB-4, and 171 (31%) had normal NFS. The proportion of false-negatives was higher in at-risk patients than the general population. FIB-4 was false-negative in 11% of diabetic subjects, compared with 2.5% false-negatives with NFS. Waist circumference outperformed FIB-4 and NFS for detecting LSM ≥8 kPa in the general population. Almost one-third (28%-29%) of elevated FIB-4/NFS were false-positive in both the general population and at-risk cohorts.
Conclusions: FIB-4 and NFS are suboptimal for screening purposes due to a high risk of overdiagnosis and a non-negligible percentage of false-negatives, especially in patients with risk factors for chronic liver disease. Waist circumference emerged as a potential first step to identify patients at risk for liver fibrosis in the general population.
Keywords: Alcoholic Liver Disease; Liver Fibrosis; NITs; Nonalcoholic Fatty Liver Disease; Noninvasive Fibrosis Scores; Screening; Transient Elastography.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Comment in
-
Reply to: Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.Clin Gastroenterol Hepatol. 2023 Jan;21(1):238-239. doi: 10.1016/j.cgh.2022.02.011. Epub 2022 Feb 11. Clin Gastroenterol Hepatol. 2023. PMID: 35151862 No abstract available.
-
Bridging the Gap: Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Population.Clin Gastroenterol Hepatol. 2022 Nov;20(11):2448-2450. doi: 10.1016/j.cgh.2022.02.029. Epub 2022 Feb 18. Clin Gastroenterol Hepatol. 2022. PMID: 35183767 No abstract available.
Similar articles
-
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.J Hepatol. 2023 Aug;79(2):277-286. doi: 10.1016/j.jhep.2023.04.002. Epub 2023 Apr 21. J Hepatol. 2023. PMID: 37088311 Clinical Trial.
-
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153. Am J Gastroenterol. 2019. PMID: 31169533
-
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.Hepatology. 2023 Jul 1;78(1):195-211. doi: 10.1097/HEP.0000000000000351. Epub 2023 Mar 17. Hepatology. 2023. PMID: 36924031
-
Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.Hepatology. 2017 Nov;66(5):1486-1501. doi: 10.1002/hep.29302. Epub 2017 Sep 26. Hepatology. 2017. PMID: 28586172 Review.
-
Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis.Eur J Clin Invest. 2022 Nov;52(11):e13855. doi: 10.1111/eci.13855. Epub 2022 Sep 7. Eur J Clin Invest. 2022. PMID: 36001034
Cited by
-
Unveiling the Role of Mechanical Microenvironment in Hepatocellular Carcinoma: Molecular Mechanisms and Implications for Therapeutic Strategies.Int J Biol Sci. 2024 Sep 30;20(13):5239-5253. doi: 10.7150/ijbs.102706. eCollection 2024. Int J Biol Sci. 2024. PMID: 39430235 Free PMC article. Review.
-
A Novel Algorithm for Streamlining Diagnosis of Advanced Liver Fibrosis in CHB Patients with Concurrent Hepatic Steatosis.J Clin Transl Hepatol. 2024 Feb 28;12(2):222-226. doi: 10.14218/JCTH.2023.00362. Epub 2024 Jan 29. J Clin Transl Hepatol. 2024. PMID: 38343608 Free PMC article.
-
Predictive Algorithm for Hepatic Steatosis Detection Using Elastography Data in the Veterans Affairs Electronic Health Records.Dig Dis Sci. 2023 Dec;68(12):4474-4484. doi: 10.1007/s10620-023-08043-8. Epub 2023 Oct 21. Dig Dis Sci. 2023. PMID: 37864738 Free PMC article.
-
Screening for NAFLD-Current Knowledge and Challenges.Metabolites. 2023 Apr 9;13(4):536. doi: 10.3390/metabo13040536. Metabolites. 2023. PMID: 37110194 Free PMC article. Review.
-
Association between liver fibrosis and the in-hospital mortality in patients with sepsis-induced coagulopathy.BMC Infect Dis. 2024 Oct 10;24(1):1136. doi: 10.1186/s12879-024-10051-6. BMC Infect Dis. 2024. PMID: 39390403 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical